Autopsy report · NCT05130983

Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease

“Enrollment challenges.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 2 months before it started.
• Ran for about 1 year 10 months before it stopped.
• 3 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Direct Biologics, LLC

Sponsor type

Industry

Conditions

Crohn Disease; Inflammatory Bowel Diseases

Interventions

ExoFlo

Participants

3

Sites

2

Countries

United States

Trials that died the same way

• The Safety of Transdermal Nicotine Immediately Following an Acute Coronary Syndrome
  “Difficulties with enrollment.” (86% match in meaning)
• A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
  “Major challenge for enrollment of participants.” (85% match in meaning)
• Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
  “Enrollment challenges, study not feasible” (83% match in meaning)
• (SGB) in Men Treated for Prostate Cancer Improve Hot Flashes
  “Enrollment issues” (83% match in meaning)
• Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts
  “Difficulties of enrollment” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.